Patent: 10,821,075
✉ Email this page to a colleague
Summary for Patent: 10,821,075
| Title: | Compositions for topical application of a medicaments onto a mammalian body surface |
| Abstract: | Drug-delivery systems are described which can serve as platforms for topical delivery of a variety of active pharmaceutical ingredients (API) to the surface of a mammalian body. Methods for the preparation and use of the compositions are also described. In some embodiments, the disclosed topical formulations include an API, a penetration enhancer/cosolvent, a gelling agent, and a neutralizing agent (to adjust pH). As compared to prior compositions, the disclosed topical formulations use a relatively small number of safe components and are easy to prepare with a high yield of finished product. |
| Inventor(s): | Blanchard James |
| Application Number: | US15648316 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,821,075
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | June 04, 1965 | ⤷ Start Trial | 2037-07-12 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | June 30, 2006 | ⤷ Start Trial | 2037-07-12 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | August 10, 2012 | ⤷ Start Trial | 2037-07-12 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | October 13, 2016 | ⤷ Start Trial | 2037-07-12 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | March 20, 2018 | ⤷ Start Trial | 2037-07-12 |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | November 18, 2011 | ⤷ Start Trial | 2037-07-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
